Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval
Year: 2019
Type: article
Source: The Lancet Psychiatry
Author: Erick H Turner
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: esketamine, treatment-resistant depression, FDA drug approval, antidepressant efficacy, antidepressant safety, NMDA receptor antagonists, ketamine, brexanolone, postpartum depression, risk-benefit assessment, breakthrough therapy designation, mental health services funding, mental health professionals
Open Access status: closed
OpenAlex ID: W2982569821
